



# Analysis of the regulation of metastasis-associated lung adenocarcinoma transcript 1 on the biological behavior of breast cancer

Xiao He<sup>1#</sup>, Qinfang Miao<sup>2#</sup>, Yi Yi<sup>1</sup>, Weijie Hu<sup>1</sup>, Min Wu<sup>1</sup>, Yiping Wu<sup>1</sup>, Qi Zhang<sup>1</sup>

<sup>1</sup>Department of Plastic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; <sup>2</sup>Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three Gorges University, Yichang, China

*Contributions:* (I) Conception and design: Y Wu, Q Zhang; (II) Administrative support: Y Wu, Q Zhang; (III) Provision of study materials or patients: Y Wu, Q Zhang; (IV) Collection and assembly of data: X He, Q Miao; (V) Data analysis and interpretation: Y Yi, W Hu, M Wu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work.

*Correspondence to:* Yiping Wu, PhD; Qi Zhang, PhD. 1095 Jiefang Avenue, Wuhan, China. Email: tongjiplastic@163.com; zhangqi06172@163.com.

**Background:** Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a class of long non-coding RNA (lncRNA) that has been proved to be closely related to many cancers.

**Methods:** The relevant research on MALAT1 in cancers published in recent years were collected and integrated. CiteSpace was employed to draw a knowledge map of MALAT1 in breast cancer, to evaluate the research front-burner issues. Then, multiple microarray data sets were searched from online data for meta-analysis to evaluate the relationship between MALAT1 and breast cancer survival rate.

**Results:** The results showed that MALAT1 had been widely studied in the proliferation and differentiation of cancer cells, and MALAT1 might regulate breast cancer through the PI3K/AKT/mTOR signaling pathway. In addition, high expression of MALAT1 had a significant correlation with relapse-free survival (HR: 1.51, 95% CI: 0.79–2.29), while there was no significant correlation between MALAT1 expression and overall survival (HR: 1.09, 95% CI: 0.63–1.72).

**Conclusions:** The expression level of lncRNA MALAT1 was closely related to cancer progression and prognosis of cancer patients. Moreover, the expression of MALAT1 was strongly associated with the survival rate of recurrence-free breast cancer. However, since the present study only adopted the existing literature for visual analysis, subsequent experiments are needed to be done to verify this conclusion. It is hoped that this work could provide a theoretical foundation for promoting the clinical adoption of MALAT1 in the prediction, diagnosis, and treatment of breast cancer, and point out a new direction for the in-depth exploration of the function of MALAT1.

**Keywords:** Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1); breast cancer; CiteSpace; meta-analysis; survival rate

Submitted Nov 07, 2020. Accepted for publication Mar 05, 2021.


doi: 10.21037/tcr-20-3221

View this article at: <http://dx.doi.org/10.21037/tcr-20-3221>

## Introduction

Breast cancer is the most common female malignancy worldwide and the leading cause of cancer-related death in women. Previous studies suggested that the occurrence and development of breast cancer were closely related to

genes, hormones, and dietary habits (1,2). With the rapid development of Genechip and high-throughput sequencing technology, the role of genes in the occurrence, development, and metastasis of tumor diseases has drawn people's close attention. In recent years, many studies revealed that long



**Figure 1** CiteSpace analysis process. The analysis process using CiteSpace was mainly divided into the following process. (I) The time node and time slicing mode were decided; (II) the analysis node type and the link type were selected; (III) the similarity or proximity of the input data was calculated; (IV) corresponding networks for each time slice were constructed; (V) whether to perform network scaling was determined. If so, network scaling was performed; if not, the time series of the network were merged; (VI) the merge of network time series after network scaling; (VII) finally, the analysis process could be ended according to whether to perform network scaling and the network after scaling with merged time series.

non-coding ribonucleic acid (lncRNA) played an important role in the regulation of transcription, post-transcription, and protein expression (3). It was also found to be involved in biological processes such as cell differentiation, genomic imprinting, and epigenetic regulation (4). lncRNA is known to be involved in the occurrence, development, and metastasis of cancer (5). Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved lncRNA, which is expressed in mammalian multi-tissue cells and can participate in epigenetic regulation and cell cycle regulation (6-8). In addition, many studies confirmed that MALAT1 was closely related to malignant tumors such as lung cancer, liver cancer, gastric cancer, and colorectal cancer. The high expression of MALAT1 was mostly found in tumor cells, which can promote the proliferation, metastasis, and invasion of tumor cells (9,10). Research of Zhang *et al.* proved that the expression of MALAT1 was correlated with the overall survival of patients after surgery (11). Studies also revealed

that MALAT1 can regulate angiogenesis through the extracellular regulated protein kinase/matrix metalloprotease pathway, thereby promoting cancer metastasis (12). However, the role of MALAT1 in the pathogenesis and development of breast cancer is still relatively rare. Therefore, the abnormal expression of MALAT1 as a biological marker for breast cancer diagnosis is still to be explored.

CiteSpace is employed in this research to analyze lncRNA MALAT1 and its potential value in the diagnosis of cancer and breast cancer. Then, meta-analysis is performed to systematically evaluate the results of relevant studies, aiming to explore the correlation between MALAT1 expression and breast cancer survival rate. This study provides a new way of thinking for the follow-up study of MALAT1 in the occurrence and metastasis of breast cancer and its effect on the prognosis of patients. We present the following article in accordance with the MDAR reporting checklist (available at <http://dx.doi.org/10.21037/tcr-20-3221>).

## Methods


### CiteSpace

The most powerful feature of the CiteSpace was that the software could perform co-cited analysis. Through the citations contained in the database, the frequency of these citations was used to be cited by other documents to perform cluster analysis. Then, the most influential citations in this field could be analyzed and obtained. Finally, the front-burner issues in this research field and the corresponding research process could be comprehended (13). The analysis process using CiteSpace was shown in *Figure 1*.

### Data collection and preprocessing

The data used for CiteSpace analysis could be collected from the Web of Science (<http://webofscience.com>), Chinese Social Science Citation Index, and China National Knowledge Infrastructure database (14). This study adopted the data in the Web of Science database to study the regulation of MALAT1 in cancer and breast cancer.

First, the subject terms “MALAT1” and “Cancer”, and “MALAT1” and “Breast Cancer” were searched in the core database of Web of Science. Then, “Article” was selected as the document type, and time span from 1996 to 2020 was determined. Finally, a total of 1,180 articles with the subject word “MALAT1” and “Cancer”, and 215 with “MALAT1” and “Breast Cancer” were retrieved. Each record was saved



**Figure 2** CiteSpace parameter setting interface. After the CiteSpace software was running, Web of Science was selected and a new program in the “Projects” column was created. The “project” folder created in the previous step was taken as the “Project Home” and the “data” folder as the “Data Directory”. (I) Time Scaling: time scaling was for setting and presenting the temporal evolution of the research data, and the time span could be selected based on the time range of the data. (II) Text Processing: this module was divided into two parts: “Term Source” and “Term Type”. (III) Network Configuration: this module was divided into three parts: “Node Types”, “Links”, and “Selection Criteria”. (IV) Pruning: the “Pathfinder and Pruning the merged network” option was chosen. (V) Visualization: the “Cluster View-Static” and “Show Merged Network” options were chosen.

as a plain text document, the record format was as follows “author, title, source publication, and abstract”, and the file name was “Download.txt”. Then, the data-import/export function in CiteSpace was taken to transform the input.

### CiteSpace parameter setting


After the CiteSpace was started, Web of Science was selected and a new program in the “Projects” column was created.

(I) Time Scaling: The time span in this research was set as from 1996 to 2020, and # Years Per Slice is set to 1. (II) Text Process It needed to select “Title, Abstract, Author Keywords (DE), and Keywords Plus (ID)” in “Term Source”. “Burst Terms” in “Term Type” was selected and “Detect Bursts”. (III) Network Configuration: “Author, Institution, Country, Keywords, Cited References, and Cited Author” in “Node Types” were selected for analysis. “Top N% per slice” option in “Selection Criteria” was selected, and set as 1% and 100, respectively. The specific parameter setting was shown in *Figure 2*. After the parameters were set, the program was started by clicking “GO!”.


### Meta-analysis

Breast cancer data sets containing *MALAT1* gene expression were extracted from the GEO database (<https://www.ncbi.nlm.nih.gov/gds>). This study adopted the data in Affymetrix human genome U133 plus 2.0 array and U133A array. Then, a total of six data sets were finally selected, namely GSE6532, GSE9195, GSE20711, GSE31448, GSE42568, and GSE1456. Third-quantile distribution meant that the *MALAT1* expression in the chip data was arranged from large to small, it was classified into low (values from 0% to 33.3%) and medium (33.3 % to 66.6%) and high (66.6% to 100%). Using the study-specific third-quantile distribution as the cutoff value, the *MALAT1* expression data was finally divided into 3 categories, which were “High” (*MALAT1* expression > high tertile cutoff), “Mid” (low tertile cutoff  $\leq$  *MALAT1* expression < high tertile cutoff), and “Low” (*MALAT1* expression  $\leq$  low tertile cutoff).

In this study, we used R language to build a proportional hazard model and used proportional hazard regression analysis to compare “High” and “Low”. RevMan 5.3 software was employed for meta-analysis, and in the meta-analysis, a random effects model (DerSimonian and Laird



**Figure 3** Statistics on the number of publications on *MALAT1* gene and cancer in different years. The number of publications with the keywords “MALAT1” and “Cancer” from 1996 to 2020 was derived from the core database of Web of Science. Horizontal and vertical axes represented the year and number of publications respectively.



**Figure 4** Statistics on the number of publications on *MALAT1* genes and cancer in different countries/regions. The number of publications with the keywords “MALAT1” and “Cancer” from 1996 to 2020 was derived from the core database of Web of Science. Horizontal and vertical axes represented the country and number of publications respectively.

method) was used to calculate the combined hazard ratio (HR) and 95% confidence interval (95% CI).

### Statistical analysis

CiteSpace software was used to construct knowledge maps related to the subject terms “MALAT1” and “Cancer”, and “MALAT1” and “Breast Cancer” to understand and


summarize the research trend of “MALAT1” in recent years. The differential expression of MALAT1 in the chip data was classified as “high”, “medium” and “low” according to the third-quantile distribution. The Cox proportional-hazards regression model was used to calculate HRs and 95% CI. Meta-analysis of MALAT1 expression and survival and recurrence of breast cancer patients was performed via using RevMan5.3 software. When  $I^2 > 50\%$  and  $P > 0.05$ , it indicated that there was heterogeneity in the data, and the random-effects model was used for analysis. When  $I^2 < 50\%$  and  $P < 0.05$ , there was no heterogeneity in the data, and the fixed-effects model was used for analysis.  $P < 0.05$  was considered significant.

## Results


### *MALAT1 and Cancer post trend analysis*

The number of articles published on the keywords “MALAT1” and “Cancer” from 1996 to 2020 was derived from the core database of Web of Science. First, the changes in the number of articles published in different years that contained the subject terms “MALAT1” and “Cancer” were compared. *Figure 3* presented that the number of publications from 2008 to 2011 was relatively small, while that from 2011 to 2018 showed an increasing trend year by year. As of August 2020, the number of publications with keywords of “MALAT1” and “Cancer” was 145, accounting for 12.288% of the total number in recent years. It revealed that the role of *MALAT1* gene in cancer had become the research focus of experts in related fields and the trend of future research. Then, the differences between different countries/regions in the number of publications on the keywords “MALAT1” and “Cancer” were analyzed. The collaborative articles were classified based on the information of the first author. *Figure 4* showed that Chinese accounted for the largest proportion in studying “MALAT1” and “Cancer”, which was more than half of the studies in recent years, followed by the American.

The number of publications on the keywords of “MALAT1” and “Breast Cancer” from 1996 to 2020 was derived from the core database of Web of Science. Firstly, the changes in the number of publications related to the publication of the keywords of “MALAT1” and “Breast Cancer” in different years were compared. *Figure 5* showed the number of publications from 2008 to 2015 was small, while the number from 2015 to 2019 increased rapidly. By August 2020, the number of articles with the keywords of



**Figure 5** Statistics on the number of publications on *MALAT1* genes and breast cancer in different years. The number of publications with the keywords of “MALAT1” and “Breast Cancer” from 1996 to 2020 was derived from the core database of Web of Science. Horizontal and vertical axes represented the year and number of publications respectively.



**Figure 6** Statistics on the number of publications on *MALAT1* genes and breast cancer in different countries/regions. The number of publications with the keywords of “MALAT1” and “Breast Cancer” from 1996 to 2020 was derived from the core database of Web of Science. Horizontal and vertical axes represented the country and number of publications respectively.

“MALAT1” and “Breast Cancer” in 2020 had reached 23, accounting for about 10.698% of the total number of articles with the keywords of “MALAT1” and “Breast Cancer” from 1996 to 2020. It indicated that the role of *MALAT1* gene in breast cancer had become a front-burner issue among experts in relevant fields and the future research trend.

Then, the differences in the number of articles published on the keywords of “MALAT1” and “Breast Cancer” in different countries/regions were analyzed. The collaborative

articles were classified based on the information of the first author. *Figure 6* showed that Chinese accounted for the largest proportion in studying “MALAT1” and “Breast Cancer”, which was more than half of the studies in recent years, followed by the American.

*Visualization results of CiteSpace knowledge map*

In CiteSpace, it set the “Top N%” and “per slice” as 1% and 100, respectively, to visualize the knowledge map of keywords. *Figure 7* showed that the keywords were mainly MALAT1, expression, metastasis, and proliferation. Different keywords were closely related to each other (15).


Through the calculation of high-frequency keywords, the centrality of high-frequency keywords in this field was obtained. *Table 1* suggested the higher the centrality, the more studies around the keyword. The keyword “MALAT1” had the highest frequency and centrality, followed by “expression” with 0.77 centrality. The keyword “metastasis” was the 3rd. These results revealed that most studies on *MALAT1* gene and cancer had focused on the expression of its lncRNA in cancer cell metastasis, proliferation, and poor prognosis of patients (16).

Log-likelihood rate (LLR) is a clustering label word extraction algorithm, which can cluster according to the citing documents. The larger the cluster label word, the more representative the word is. Subsequently, through the LLR method, clustering of high-frequency keywords had been achieved using a total of three cluster labels (long, clinicopathology, and micRNA, respectively). Thus, MALAT1 gene was a type of long non-coding RNA (lncRNA), which might regulate miRNAs associated with certain diseases, and then played a role in regulating the clinicopathological changes of cancer. Moreover, the description of the three keyword cluster tags was given in *Table 2*. It could be known that the key words based on clustering, MALAT1, and cancer-related published key word clustering tags were mostly asthmatic diseases or clinicopathological studies.

By calculating the highly cited authors, the centrality of the highly cited authors in this field could be obtained (11,17-26), as shown in *Table 3*.

Then, the highly cited literature clustering was performed by the LLR method, and a total of nine clustering tags (sunitinib, regulates, tumorigenesis, characterization, migration, metastasis-associated, transition, suppressor, and mir-9) were obtained in *Figure 8*. The clustering tags of the highly cited publications focused on the characterization and





**Figure 7** Clusters of core keywords of *MALAT1* gene and cancer. In CiteSpace, it set the “Top N%” and “per slice” as 1% and 100, respectively, to visualize the knowledge map of keywords.

**Table 1** The top 10 keywords related to *MALAT1* gene and cancer

Rank	Frequency	Centrality	Year	Keywords
1	248	0.96	2018	MALAT1
2	209	0.77	2018	Expression
3	209	0.75	2018	Metastasis
4	140	0.68	2018	Proliferation
5	117	0.59	2018	LncRNA
6	113	0.57	2018	Cancer
7	112	0.53	2018	Invasion
8	85	0.46	2018	Poor-prognosis
9	84	0.44	2018	LncRNA
10	77	0.42	2019	Migration

MALAT1, metastasis associated lung adenocarcinoma transcript 1; lncRNA, long noncoding RNA. Year: the year when the keyword appears frequently.

**Table 2** Clustering tags of core keywords of *MALAT1* gene and cancer

ID	Size	Silhouette	Mean (year)	Terms (mutual information)
0#	5	0.913	2018	Asthmatic
1#	3	0.532	2018	Clinicopathology
2#	2	0.487	2018	Clinicopathology

MALAT1, metastasis associated lung adenocarcinoma transcript 1.

regulation of *MALAT1* gene in tumors (27). It was suggested that MALAT1 was closely related to the progression of cancer and might interact with the regulation of cancer through sunitinib or *mir-9* gene. Since this study was based on big data, analysis software was adopted to obtain

assumptions, experiments were still needed for verifying.

Through the calculation of high-frequency keywords, the centrality of high-frequency keywords in this field was obtained. *Table 4* showed that the keyword “MALAT1” had the highest frequency and the highest centrality.

Visualization of knowledge map of highly cited articles was performed, and the centrality of highly cited articles in this field was calculated (17-21,24,25,28,29), as shown in *Table 5*. The articles of the author Ji P [2003] had the highest citation frequency, followed by those published by Gutschner T [2013]. The Centrality of Tripathi V [2010], Arun G [2016], and Yang LQ [2011] was lower than 0.1, and the Centrality of other high-frequency citation was no less than 0.1.

Then, through the clustering of highly cited publications by the LLR method, 5 clustering tags (breast, long, PI3K/AKT/mTOR, coding, and -coding) were obtained. *Figure 9* revealed that the clustering tags of highly cited publications were concentrated in *MALAT1* gene, breast, and PI3K/AKT/mTOR signaling pathway. It was suggested that MALAT1 might regulate breast cancer through PI3K/AKT/mTOR signaling pathway (30).


**Results of meta-analysis**

A meta-analysis of the association between MALAT1 expression and breast cancer survival was explored based on the analysis results of 6 GEO datasets. Meta-analysis results in *Figure 10* showed that high expression of MALAT1 was significantly correlated with relapse-free survival (HR: 1.51, 95% CI: 0.79–2.29, *Figure 10A*), while there was no significant correlation between MALAT1 expression and overall survival (HR: 1.09, 95% CI: 0.63–1.72), as shown in *Figure 10B*.

**Table 3** The top 10 highly cited publications on *MALAT1* genes and cancer

Rank	Frequency	Centrality	Year	Cited references
1	139	0.47	2003	Ji P, 2003, <i>Oncogene</i> , V22, P8031, DOI 10.1038/S.J.ONC.1206928
2	110	0.27	2013	Gutschner T, 2013, <i>Cancer Res</i> , V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
3	84	0.15	2013	Gutschner T, 2013, <i>J Mol Med (Berl)</i> , V91, P791, DOI 10.1007/S00109-013-1028-Y
4	77	0.22	2010	Tripathi V, 2010, <i>Mol Cell</i> , V39, P925, DOI 10.1016/J.MOLCEL.2010.08.011
5	65	0.95	2015	Hirata H, 2015, <i>Cancer Res</i> , V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931
6	61	0.17	2010	Gupta RK, 2010, <i>Nature</i> , V464, P1071, DOI 10.1038/NATURE08975
7	52	0.11	2011	Schmidt LH, 2011, <i>J Thorac Oncol</i> , V6, P1984, DOI 10.1097/JTO.0B013E3182307EAC
8	51	1.03	2014	Fan Y, 2014, <i>Clin Cancer Res</i> , V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455
9	50	0.11	2016	Arun G, 2016, <i>Gene Dev</i> , V30, P34, DOI 10.1101/GAD.270959.115
10	46	0.30	2014	Zheng HT, 2014, <i>Int J Clin Exp Pathol</i> , V7, P3174

MALAT1, metastasis associated lung adenocarcinoma transcript 1.



**Figure 8** LLR-based clusters of core highly cited publications on *MALAT1* gene and cancer. The highly cited literature clustering was performed by the LLR method, and a total of nine clustering tags (sunitinib, regulates, tumorigenesis, characterization, migration, metastasis-associated, transition, suppressor, and mir-9) were obtained.

**Table 4** The top 10 keywords related to *MALAT1* gene and breast cancer

Rank	Frequency	Centrality	Year	Keywords
1	84	1.00	2016	MALAT1
2	62	0.86	2018	Expression
3	59	0.75	2016	Metastasis
4	59	0.75	2017	Breast-cancer

MALAT1, metastasis associated lung adenocarcinoma transcript 1. Year: the year when the keyword appears frequently.


### Discussion

Studies have revealed that elevated MALAT1 expression levels are closely related to the prognosis of breast cancer patients. Zheng *et al.* [2019] found that the expression of MALAT1 in breast cancer tissues increased significantly, and the overall survival rate was negatively correlated with the expression of MALAT1, indicating that MALAT1 was a potential prognostic factor (31). Sun *et al.* [2020] detected a significant increase in the expression level of MALAT1 in the serum of breast cancer patients (32). Then, they found that the MALAT1 level of patients was significantly reduced after treatment, and that the MALAT1 level of patients with

**Table 5** The top 10 highly cited publications on *MALAT1* genes and breast cancer

Rank	Frequency	Centrality	Year	Cited references
1	64	0.55	2003	Ji P, 2003, <i>Oncogene</i> , V22, P8031, DOI 10.1038/S.J.ONC.1206928
2	54	0.43	2013	Gutschner T, 2013, <i>Cancer Res</i> , V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
3	41	0.07	2010	Tripathi V, 2010, <i>Mol Cell</i> , V39, P925, DOI 10.1016/J.MOLCEL.2010.08.011
4	35	0.27	2010	Gupta RK, 2010, <i>Nature</i> , V464, P1071, DOI 10.1038/NATURE08975
5	32	0.32	2013	Gutschner T, 2013, <i>J Mol Med (Berl)</i> , V91, P791, DOI 10.1007/S00109-013-1028-Y
6	30	0.35	2015	Hirata H, 2015, <i>Cancer Res</i> , V75, P1322, DOI 10.1158/0008-5472.CAN-14-2931
7	30	0.01	2016	Arun G, 2016, <i>Gene Dev</i> , V30, P34, DOI 10.1101/GAD.270959.115
8	26	0.10	2014	Fan Y, 2014, <i>Clin Cancer Res</i> , V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455
9	25	0.02	2011	Yang LQ, 2011, <i>Cell</i> , V147, P773, DOI 10.1016/J.CELL.2011.08.054
10	23	0.08	2009	Ponting CP, 2009, <i>Cell</i> , V136, P629, DOI 10.1016/J.CELL.2009.02.006

MALAT1, metastasis associated lung adenocarcinoma transcript 1.



**Figure 9** LLR-based clusters of core highly cited publications on *MALAT1* gene and breast cancer. Through the clustering of highly cited publications by the LLR method, 5 clustering tags (breast, long, PI3K/AKT/mTOR, coding, and -coding) were obtained.


good prognosis was significantly lower than that of patients with poor prognosis. In our study, MALAT1 expression data from the GEO database were used, and the results showed that high MALAT1 expression was significantly associated with relapse-free survival, but not with overall survival. This conclusion is slightly different from previous studies and may be caused by the selection and sample size of MALAT1 data in GEO database. This association may remain significant after adjustment for age at surgery, disease stage, tumor grade, and hormone receptor status due to the complexity of breast cancer staging and typing. Totally, it could be inferred that the increase of MALAT1 expression level could lead to poor prognosis of breast cancer patients, and then increased the mortality rate. Unfortunately, there has been no report on the role of MALAT1 in male breast cancer. The reason for this is that the incidence of male breast cancer is much lower than in women. As a result, in the actual research process, the

isolated tumor samples of male breast cancer are difficult to obtain and is relatively of small number. Besides, the research value is far lower than that of female breast cancer. However, it is possible from existing studies that MALAT1 may also be a pro-tumor regulator in male breast cancer. Of course, this question is worth exploring further.

## Conclusions

The core data of Web of Science were taken to collect the literature related to MALAT1, cancer, and breast cancer in recent years. CiteSpace was adopted to visualize the correlation of different keywords. The results revealed that the lncRNA expression level of MALAT1 was closely related to cancer progression and prognosis of cancer patients. Moreover, it was also found that the expression of MALAT1 was closely related to the survival rate of recurrence-free breast cancer. However, it only adopted





**Figure 10** Meta-analysis of the correlation between MALAT1 expression and breast cancer survival. (A) The correlation between MALAT1 expression and recurrence-free survival; (B) The correlation between MALAT1 expression and overall survival rate. The 95% CI value was the correlation value between MALAT1 expression obtained by proportional hazard model analysis and patient survival rate and recurrence-free rate.

the existing literature for visual analysis, and subsequent experiments needed to be done to verify this conclusion. We hope that the results can provide evidence for lncRNA MALAT1 as a biological marker for diagnosis and treatment of breast cancer.

**Acknowledgments**

*Funding:* This work was supported by the China Guanghua Science and Technology Foundation (grant number 2019JZXM001) and the Wuhan Science and Technology Bureau (grant number 2020020601012241).

**Footnote**

*Reporting Checklist:* The authors have completed the MDAR reporting checklist. Available at <http://dx.doi.org/10.21037/tcr-20-3221>

*Peer Review File:* Available at <http://dx.doi.org/10.21037/tcr-20-3221>

*Conflicts of Interest:* All authors have completed the ICMJE

uniform disclosure form (available at <http://dx.doi.org/10.21037/tcr-20-3221>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

**References**

1. Prowell TM, Beaver JA, Pazdur R. Neoadjuvant or adjuvant chemotherapy in early breast cancer? J Pathol

- 2019;247:612-5.
2. Egger SS, Bachmann A, Hubmann N, et al. Prevalence of potentially inappropriate medication use in elderly patients: comparison between general medical and geriatric wards. *Drugs Aging* 2006;23:823-37.
  3. Jathar S, Kumar V, Srivastava J, et al. Technological Developments in lncRNA Biology. *Adv Exp Med Biol* 2017;1008:283-323.
  4. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *N Engl J Med* 2018;378:345-53.
  5. Assefa AT, De Paepe K, Everaert C, et al. Differential gene expression analysis tools exhibit substandard performance for long non-coding RNA-sequencing data. *Genome Biol* 2018;19:96.
  6. Dai W, Tian Y, Jiang B, et al. Down-regulation of long non-coding RNA AFAP1-AS1 inhibits tumor growth, promotes apoptosis and decreases metastasis in thyroid cancer. *Biomed Pharmacother* 2018;99:191-7.
  7. Yang H, Wang S, Kang YJ, et al. Long non-coding RNA SNHG1 predicts a poor prognosis and promotes colon cancer tumorigenesis. *Oncol Rep* 2018;40:261-71.
  8. Shu J, Li S, Chen YB, et al. Long non-coding RNA EPB41L4A-AS2 inhibited non-small cell lung cancer proliferation, invasion and promoted cell apoptosis. *Neoplasma* 2018;65:664-72.
  9. Jin Y, Feng SJ, Qiu S, et al. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. *Eur Rev Med Pharmacol Sci* 2017;21:3176-84.
  10. Xiao Y, Pan J, Geng Q, et al. LncRNA MALAT1 increases the stemness of gastric cancer cells via enhancing SOX2 mRNA stability. *FEBS Open Bio* 2019;9:1212-22.
  11. Zhang HM, Yang FQ, Chen SJ, et al. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. *Tumour Biol* 2015;36:2947-55.
  12. Lei L, Zeng Q, Lu J, et al. MALAT1 participates in ultraviolet B-induced photo-aging via regulation of the ERK/MAPK signaling pathway. *Mol Med Rep* 2017;15:3977-82.
  13. Liu GF. Visualization of patents and papers in terahertz technology: a comparative study. *Scientometrics* 2013;94:1037-56.
  14. Peterson AE, Bond GR, Drake RE, et al. Predicting the Long-Term Sustainability of Evidence-Based Practices in Mental Health Care: An 8-Year Longitudinal Analysis. *J Behav Health Serv Res* 2014;41:337.
  15. Lin Q, Guan W, Ren W, et al. MALAT1 affects ovarian cancer cell behavior and patient survival. *Oncol Rep* 2018;39:2644-52.
  16. Stone JK, Kim JH, Vukadin L, et al. Hypoxia induces cancer cell-specific chromatin interactions and increases MALAT1 expression in breast cancer cells. *J Biol Chem* 2019;294:11213-24.
  17. Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene* 2003;22:8031-41.
  18. Gutschner T, Hämmerle M, Diederichs S. MALAT1--a paradigm for long noncoding RNA function in cancer. *J Mol Med (Berl)* 2013;91:791-801.
  19. Gutschner T, Hämmerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res* 2013;73:1180-9.
  20. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. *Mol Cell* 2010;39:925-38.
  21. Hirata H, Hinoda Y, Shahryari V, et al. Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205. *Cancer Res* 2015;75:1322-31.
  22. Gupta RK, Arany Z, Seale P, et al. Transcriptional control of preadipocyte determination by Zfp423. *Nature* 2010;464:619-23.
  23. Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. *J Thorac Oncol* 2011;6:1984-92.
  24. Fan Y, Shen B, Tan M, et al. TGF- $\beta$ -Induced Upregulation of malat1 Promotes Bladder Cancer Metastasis by Associating with suz12. *Clin Cancer Res* 2014;20:1531-41.
  25. Arun G, Diermeier S, Akerman M, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. *Genes Dev* 2016;30:34-51.
  26. Zheng HT, Shi DB, Wang YW, et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. *Int J Clin Exp Pathol* 2014;7:3174-81.
  27. Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. *Nat Genet* 2018;50:1705-15.
  28. Yang L, Lin C, Liu W, et al. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. *Cell* 2011;147:773-88.

29. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. *Cell* 2009;136:629-41.
30. Xu S, Sui S, Zhang J, et al. Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. *Int J Clin Exp Pathol* 2015;8:4881-91.
31. Zheng L, Zhang Y, Fu Y, et al. Long non-coding RNA MALAT1 regulates BLCAP mRNA expression through binding to miR-339-5p and promotes poor prognosis in breast cancer. *Biosci Rep* 2019;39:BSR20181284.
32. Sun Z, Liu J, Liu J. The expression of lncRNA-MALAT1 in breast cancer patients and its influences on prognosis. *Cell Mol Biol* 2020;66:72-8.

**Cite this article as:** He X, Miao Q, Yi Y, Hu W, Wu M, Wu Y, Zhang Q. Analysis of the regulation of metastasis-associated lung adenocarcinoma transcript 1 on the biological behavior of breast cancer. *Transl Cancer Res* 2021;10(4):1609-1619. doi: 10.21037/tcr-20-3221